GSK 4418959
Alternative Names: GSK-4418959; GSK-959; IDE-275Latest Information Update: 04 Jul 2025
At a glance
- Originator IDEAYA Biosciences
- Developer GSK
- Class Antineoplastics; Small molecules
- Mechanism of Action Werner syndrome helicase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamic data from a preclinical trial in Solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Ideaya Biosciences plans a clinical trial for MSI-H cancers (Second-line therapy or greater)
- 13 Dec 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Inoperable/Unresectable, Second-line therapy or greater) in Japan, USA (PO) (NCT06710847)